Preclinical evaluations of norcantharidin-loaded intravenous lipid microspheres with low toxicity

Bibliography

• Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989;26:147-62
   PubMed Web of Science ®Google Scholar
• Fang Y, Tian SL, Li KQ, Studies on antitumor agents II: synthesis and anticancer activity of dehydrogenated carboncyclic analogs of norcantharidin. Yao Xue Xue Bao 1993;28:931-5
   PubMedGoogle Scholar
• Li JL, Cai YC, Liu XH, Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anticancer Drugs 2006;17:307-14
   PubMed Web of Science ®Google Scholar
• Chen YN, Chen JC, Yin SC, Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 2002;100:158-65
   PubMed Web of Science ®Google Scholar
• Chen YN, Cheng CC, Chen JC, Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun-NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells. Br J Pharmacol 2003;140:461-70
   Google Scholar
• Yi SN, Wass J, Vincent P, Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 1991;15:883-6
   PubMed Web of Science ®Google Scholar
• Liu XH, Blazsek I, Comisso M, Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer 1995;31A:953-63
   PubMed Web of Science ®Google Scholar
• Dorn DC, Kou CA, Png KJ, The effect of cantharidins on leukemic stem cells. Int J Cancer 2009;124:2186-99
   PubMed Web of Science ®Google Scholar
• Dong C. Study on distribution of 3H-norcantharidin in mice. J Acad Med Jiangxi 1984;24:3-6
   Google Scholar
• Yan Z, Mao SZ, Gong YS. A dynamic observation or multiple organ dysfunction syndrome caused by norcantharidin in rats. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 1999;1:737-8
   Google Scholar
• Bei YY, Chen XY, Liu Y, Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption. Int J Nanomedicine 2012;7:1819-27
   PubMed Web of Science ®Google Scholar
• Li B, Zhu LF, Zhang YN, Comparison of acute toxicity of two preparations of norcantharidin in mice. Zhong Xi Yi Jie He Xue Bao 2007;5:74-7
   PubMedGoogle Scholar
• Wang S, Guo S. Disodium norcantharidate-loaded poly(epsilon-caprolactone) microspheres II. Modification of morphology and release behavior. Int J Pharm 2008;353:15-20
   PubMed Web of Science ®Google Scholar
• Wang S, Guo S, Cheng L. Disodium norcantharidate loaded poly(epsilon-caprolactone) microspheres I. Preparation and evaluation. Int J Pharm 2008;350:130-7
   PubMed Web of Science ®Google Scholar
• Liu X, Heng WS, Paul Novel polymeric microspheres containing norcantharidin for chemoembolization. J Control Release 2006;116:35-41
   PubMed Web of Science ®Google Scholar
• Zhang L, Sun X, Zhang ZR. An investigation on liver-targeting microemulsions of norcantharidin. Drug Deliv 2005;12:289-95
   PubMed Web of Science ®Google Scholar
• Zeng QB, Sun M. Poly (lactide-co-glycolide) nanoparticles as carriers for norcantharidin. Mater Sci Eng C 2009;29:708-13
   Web of Science ®Google Scholar
• Wang Q, Zhang L, Hu W, Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery. Nanomedicine 2010;6:371-81
   PubMed Web of Science ®Google Scholar
• Guan M, Zhou Y, Zhu QL, N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy. Nanomedicine: NBM 2012;xx:1-10
   Google Scholar
• Nasirideen S, Kas HS, Oner F, Naproxen incorporated lipid emulsions. I. Formulation and stability studies. J Clin Pharm Ther 1998;23:57-65
   PubMed Web of Science ®Google Scholar
• Igarashi R, Takenaga M, Matsuda T. Distribution of lipid microsphere preparations. Adv Drug Deliv Rev 1996;20:147-54
   Web of Science ®Google Scholar
• Patlolla RR, Vobalaboina V. Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. J Pharm Sci 2005;94:437-45
   PubMed Web of Science ®Google Scholar
• Fukui H, Koike T, Nakagawa T, Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations. Int J Pharm 2003;267:101-12
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11:812-18
   PubMed Web of Science ®Google Scholar
• Narang AS, Varia S. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev 2011;63:640-58
   PubMed Web of Science ®Google Scholar
• Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2010;2:14
   PubMedGoogle Scholar
• Ichimura K, Stan RV, Kurihara H, Glomerular endothelial cells form diaphragms during development and pathologic conditions. J Am Soc Nephrol 2008;19:1463-71
   PubMed Web of Science ®Google Scholar
• Snoeys J, Lievens J, Wisse E, Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther 2007;14:604-12
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Wigler N, Inbar M, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9
   PubMed Web of Science ®Google Scholar
• Lee CW, Hong DH, Han SB, A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-on e, has antitumor efficacy in in vitro and in vivo tumor models. Biochem Pharmacol 2002;64:473-80
   PubMed Web of Science ®Google Scholar
• Li D, Liu Z, Cui Y, Toxicity of cyanobacterial bloom extracts from Taihu Lake on mouse, Mus musculus. Ecotoxicology 2011;20:1018-25
   PubMed Web of Science ®Google Scholar
• Le Garrec D, Gori S, Luo L, Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release 2004;99:83-101
   PubMed Web of Science ®Google Scholar
• Wei C, Teng Y, Wang B, Separation and identification of norcantharidin metabolites in vivo by GC-MS method. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:1741-7
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Watanabe K, Hayashi M, Effect of egg yolk phospholipids plasma elimination and tissue distribution of coenzyme Q10 administered in an emulsion to rats. J Pharm Pharmacol 1984;36:766-7
   PubMed Web of Science ®Google Scholar
• Mizushima Y, Hamano T, Yokoyama K. Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann Rheum Dis 1982;41:263-7
   PubMed Web of Science ®Google Scholar
• Grimes G, Vermess M, Gallelli JF, Formulation and evaluation of ethiodized oil emulsion for intravenous hepatography. J Pharm Sci 1979;68:52-6
   PubMed Web of Science ®Google Scholar
• Takino T, Konishi K, Takakura Y, Long circulating emulsion carrier systems for highly lipophilic drugs. Biol Pharm Bull 1994;17:121-5
   PubMed Web of Science ®Google Scholar
• Liang WQ. editor. Biopharmaceutics and pharmacokinetics. 2nd edition. People's Medical Publishing House; Beijing: 2005
   Google Scholar
• Lixin W, Haibing H, Xing T, A less irritant norcantharidin lipid microspheres: formulation and drug distribution. Int J Pharm 2006;323:161-7
   PubMed Web of Science ®Google Scholar
• Tamilvanan S. Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems. Prog Lipid Res 2004;43:489-533
   PubMed Web of Science ®Google Scholar